52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 66

Background

The standard treatment for early breast cancer with node-negative axilla is wide local excision (WLE) and sentinel lymph node biopsy (SNB). Guide-wire WLE for impalpable cancers poses various challenges. The use of magnetic seeds has been adopted as an alternative solution. Difficult detectability, magnetic interference with metallic instruments/MRI, and recalibration remain open issues. The common technique for SNB is radioisotope with or without blue dye. The radioisotope poses various problems including handling and disposal of isotopes. The short half-life of the isotope restricts the scheduling of surgery and hinders patients’ flow into the operating theater. Finally, concerns have previously been raised regarding the efficacy of ICG in patients with high body mass index (BMI). We present our experience in WLE plus SNB using a non-wire, non-magnetic breast localization method plus non-radioisotope technique for sentinel node identification. A comparison with the magnetic breast localization method is provided. The aims of the study are:

  1. Compare oncological clearance of cancer between magnetic and nonmagnetic localization seeds.
  2. Demonstrate a good identification rate of SNB using a
    non-radioisotope fluorescent dye.
  3. Confirm good node detection rate with the ICG regardless of patients’ BMI.

Methods

Patient and Tumor Characteristics of Patients Having WLE With SAVI SCOUT and Magseed

Patient and Tumor Characteristics of Patients Having WLE With SAVI SCOUT and Magseed

We compared 50 patients with WLE and SNB using SAVI SCOUT plus ICG with 50 cases using Magseed plus ICG in 2022/2023. The SAVI SCOUT clip was placed 1 to 5 days before surgery. Additionally, 2 mL of ICG and 2 mL of blue dye were injected intradermally in the periareolar area.

Results

The identification rate of SNB with ICG dye was 100% despite high BMI. Also, BMI has not affected the number of nodes retrieved (average number of SNB was 2, similar to other case series). A total of 5 of the patients localized with SAVI SCOUT had positive margins (10%) compared with 6 localized with magnetic seed (12%). The re-excision rate using SAVI SCOUT/Magseed is not statistically significant. Compared with guide wire, the use of SAVI SCOUT reduced the re-excision rate by 50% in our case series (15% vs 10%).

Conclusions

Non-magnetic localization of impalpable breast cancers showed a good detection rate with adequate margins clearance (10% re-excision rate, compared with 17.2% UK average). The use of ICG in SNB (with blue dye) is associated with an identification rate of 100% regardless of high BMI. Preoperative admission and preparation for surgery are streamlined by avoiding the need for wire localization and radioisotope injection.

Articles in this issue

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)
27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content